Calando Pharmaceuticals Inc., a majority-owned subsidiary of Arrowhead Research Corporation has provided more detail on its product and business goals for 2007. "We have made considerable progress ...
Courage and cleverness, those were two of the adjectives used by Grand Prix rider Harold Chopping to describe Aiken-resident Paddy Ann Burns’ Zangersheide gelding Calando Z. The rider/horse ...
PASADENA, Calif. - November 4, 2009 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its majority owned subsidiary, Calando Pharmaceuticals, Inc ...
Calando Pharmaceuticals, a subsidiary of Arrowhead Research, has struck a licensing deal with Cerulean Pharma for Calando's drug delivery platform, Cyclosert, and the associated clinical stage ...
Calando recently proved systemic siRNA delivery and RNAi-mediated mRNA knockdown. Arrowhead Research has increased its ownership of majority-owned subsidiary Calando Pharmaceuticals through the ...
WHEN EXECUTIVES from Calando Pharmaceuticals met with the management team of Agilent Technologies' nucleic acid solutions division, the chemistry was obvious, says John Petrovich, Calando's chief ...
Alnylam has the right to opt-in on development and commercialization. Alnylam Pharmaceuticals granted Calando Pharmaceuticals an InterfeRx™ license to discover, develop, and commercialize a synthetic ...
Identify research insights to guide research strategy and grow your impact with our Nature Strategy reports. Actionable insights into research performance. Detailed analysis of strengths and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results